{"id":12369,"date":"2023-10-26T09:35:00","date_gmt":"2023-10-26T01:35:00","guid":{"rendered":"https:\/\/flcube.com\/?p=12369"},"modified":"2024-11-13T09:39:25","modified_gmt":"2024-11-13T01:39:25","slug":"danaher-corporation-reports-q3-2023-earnings-with-10-5-global-revenue-decline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=12369","title":{"rendered":"Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline"},"content":{"rendered":"\n<p>US-based science and tech services giant Danaher Corporation (<a href=\"https:\/\/www.google.com\/finance\/quote\/DHR:NYSE\">NYSE: DHR<\/a>) has reported its Q3 2023 earnings, with global revenues experiencing a 10.5% year-on-year (YOY) decline to USD 6.9 billion, resulting in net earnings of USD 1.1 billion. CEO Rainer M. Blair highlighted that revenues surpassed forecasts, driven by increased respiratory testing revenue that counterbalanced the softer life sciences demand.<\/p>\n\n\n\n<p><strong>Market Performance and Business Unit Results<\/strong><br>The revenue decline was evident across all markets, with &#8216;developed markets&#8217; witnessing a low double-digit decrease, primarily due to reduced COVID-19 revenues. &#8216;High growth markets&#8217; experienced high single-digit declines, including a mid-teens drop in China. By business unit, the biotechnology unit saw a 19% YOY revenue decrease to USD 1.66 billion, Life Sciences fell by 1% to USD 1.7 billion, and Diagnostics dropped by 16% to USD 2.25 billion.<\/p>\n\n\n\n<p><strong>Spin-Off of Environmental and Applied Solutions Unit<\/strong><br>Notably, this quarter marked the last for Danaher to report results from its Environmental and Applied Solutions unit, which was spun off and launched as Veralto in September. The unit reported a 3.5% growth to USD 1.2 billion. CEO Blair emphasized that the spin-off allows Danaher to sharpen its focus on life sciences and diagnostics services.<\/p>\n\n\n\n<p><strong>China Market Challenges<\/strong><br>China, accounting for approximately 12% of Danaher\u2019s overall revenues, faced a tough quarter due to a challenging economic landscape. Bioprocessing demand plummeted globally, with China experiencing a significant 45% YOY drop, attributed to a weak funding environment and low activity levels. Blair noted that customers are still managing pandemic-era inventory and aiming to conserve capital due to funding pressures.<\/p>\n\n\n\n<p><strong>Impact of Anti-Corruption Initiatives<\/strong><br>The Life Sciences segment in China underperformed expectations, partly due to recent anti-corruption initiatives that slowed equipment tenders and installations. Meanwhile, the Diagnostics business in China has largely returned to pre-Covid trends and patient volumes. Blair acknowledged that current conditions in China may persist into 2024 but anticipates China will remain a key growth driver for Danaher in the long term.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US-based science and tech services giant Danaher Corporation (NYSE: DHR) has reported its Q3 2023&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[535,27,1265],"class_list":["post-12369","post","type-post","status-publish","format-standard","hentry","category-company","tag-danaher","tag-finanical-reports","tag-nyse-dhr"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based science and tech services giant Danaher Corporation (NYSE: DHR) has reported its Q3 2023 earnings, with global revenues experiencing a 10.5% year-on-year (YOY) decline to USD 6.9 billion, resulting in net earnings of USD 1.1 billion. CEO Rainer M. Blair highlighted that revenues surpassed forecasts, driven by increased respiratory testing revenue that counterbalanced the softer life sciences demand.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=12369\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=12369\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-26T01:35:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-13T01:39:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12369#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12369\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline\",\"datePublished\":\"2023-10-26T01:35:00+00:00\",\"dateModified\":\"2024-11-13T01:39:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12369\"},\"wordCount\":323,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Danaher\",\"Finanical Reports\",\"NYSE: DHR\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12369#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12369\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=12369\",\"name\":\"Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-10-26T01:35:00+00:00\",\"dateModified\":\"2024-11-13T01:39:25+00:00\",\"description\":\"US-based science and tech services giant Danaher Corporation (NYSE: DHR) has reported its Q3 2023 earnings, with global revenues experiencing a 10.5% year-on-year (YOY) decline to USD 6.9 billion, resulting in net earnings of USD 1.1 billion. CEO Rainer M. Blair highlighted that revenues surpassed forecasts, driven by increased respiratory testing revenue that counterbalanced the softer life sciences demand.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12369#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12369\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12369#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline - Insight, China&#039;s Pharmaceutical Industry","description":"US-based science and tech services giant Danaher Corporation (NYSE: DHR) has reported its Q3 2023 earnings, with global revenues experiencing a 10.5% year-on-year (YOY) decline to USD 6.9 billion, resulting in net earnings of USD 1.1 billion. CEO Rainer M. Blair highlighted that revenues surpassed forecasts, driven by increased respiratory testing revenue that counterbalanced the softer life sciences demand.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=12369","og_locale":"en_US","og_type":"article","og_title":"Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=12369","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-10-26T01:35:00+00:00","article_modified_time":"2024-11-13T01:39:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=12369#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=12369"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline","datePublished":"2023-10-26T01:35:00+00:00","dateModified":"2024-11-13T01:39:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=12369"},"wordCount":323,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Danaher","Finanical Reports","NYSE: DHR"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=12369#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=12369","url":"https:\/\/flcube.com\/?p=12369","name":"Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-10-26T01:35:00+00:00","dateModified":"2024-11-13T01:39:25+00:00","description":"US-based science and tech services giant Danaher Corporation (NYSE: DHR) has reported its Q3 2023 earnings, with global revenues experiencing a 10.5% year-on-year (YOY) decline to USD 6.9 billion, resulting in net earnings of USD 1.1 billion. CEO Rainer M. Blair highlighted that revenues surpassed forecasts, driven by increased respiratory testing revenue that counterbalanced the softer life sciences demand.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=12369#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=12369"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=12369#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12369"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12369\/revisions"}],"predecessor-version":[{"id":12370,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12369\/revisions\/12370"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}